Top Qs
Timeline
Chat
Perspective
Naxagolide
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
Naxagolide (INN ), also known as PHNO, dopazinol, L-647339, and MK-458 among other synonyms, is a dopamine receptor agonist which was developed for the treatment of Parkinson's disease but was never marketed.[1][2][3][4] A radiolabeled form has been used for brain imaging.[5][3] The drug was developed for use both orally and transdermally.[4][6]
It acts as a potent dopamine D2 and D3 receptor agonist.[6][7] Naxagolide was described in the 1990s as the most potent dopamine D2 receptor agonist that had been used.[8][9] It shows about 50-fold selectivity for the dopamine D3 receptor over the dopamine D2 receptor (Ki = 0.16 nM vs. 8.5 nM).[7] The drug is a naphthoxazine derivative.[6] It is structurally similar to ergolines such as pergolide and cabergoline but is a non-ergoline itself.[10][9]
Naxagolide was first described in 1984 and was under development by Merck & Co in the 1980s and 1990s.[3][4] It was developed for treatment of Parkinson's disease and reached phase 2 clinical trials for this indication.[3] The drug was discontinued due to inadequate effectiveness and/or due to toxicity.[6][8]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads